Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Stathis A, Pirosa MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Devizzi L, Haioun C, Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. Stathis A, et al. Among authors: palombi f. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.283918. Online ahead of print. Haematologica. 2024. PMID: 38385243 Free article.
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. Zinzani PL, et al. Among authors: palombi f. Haematologica. 1999 Nov;84(11):996-1001. Haematologica. 1999. PMID: 10553159 Clinical Trial.
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E, Bellei M, Amorim S, Ferreri AJM, Marcheselli L, Cesaretti M, Haioun C, Mancuso S, Bouabdallah K, Gressin R, Tripodo C, Traverse-Glehen A, Baseggio L, Zupo S, Stelitano C, Castagnari B, Patti C, Alvarez I, Liberati AM, Merli M, Gini G, Cabras MG, Dupuis J, Tessoulin B, Perrot A, Re F, Palombi F, Gulino A, Zucca E, Federico M, Thieblemont C. Iannitto E, et al. Among authors: palombi f. Br J Haematol. 2018 Dec;183(5):755-765. doi: 10.1111/bjh.15641. Epub 2018 Nov 8. Br J Haematol. 2018. PMID: 30407629 Free article. Clinical Trial.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Santoro A, Mazza R, Spina M, Califano C, Specchia G, Carella M, Consoli U, Palombi F, Musso M, Pulsoni A, Kovalchuk S, Bonfichi M, Ricci F, Fabbri A, Liberati AM, Rodari M, Giordano L, Chimienti E, Balzarotti M, Sorasio R, Gallamini A, Ghiggi C, Ciammella P, Ricardi U, Chauvie S, Carlo-Stella C, Merli F. Santoro A, et al. Among authors: palombi f. Ann Hematol. 2021 Oct;100(10):2547-2556. doi: 10.1007/s00277-021-04604-x. Epub 2021 Jul 30. Ann Hematol. 2021. PMID: 34327561 Clinical Trial.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: palombi f. Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109. Online ahead of print. Haematologica. 2024. PMID: 38497158 Free article.
Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?
Marchesi F, Pimpinelli F, Di Domenico EG, Renzi D, Gallo MT, Regazzo G, Rizzo MG, Gumenyuk S, Toma L, Marino M, Cordone I, Cantonetti M, Liberati AM, Montanaro M, Ceribelli A, Prignano G, Palombi F, Romano A, Papa E, Pisani F, Spadea A, Arcese W, Ensoli F, Mengarelli A. Marchesi F, et al. Among authors: palombi f. Int J Mol Sci. 2019 Mar 19;20(6):1373. doi: 10.3390/ijms20061373. Int J Mol Sci. 2019. PMID: 30893777 Free PMC article.
MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
Rinaldi F, Marchesi F, Palombi F, Pelosi A, Di Pace AL, Sacconi A, Terrenato I, Annibali O, Tomarchio V, Marino M, Cantonetti M, Vaccarini S, Papa E, Moretta L, Bertoni F, Mengarelli A, Regazzo G, Rizzo MG. Rinaldi F, et al. Among authors: palombi f. Br J Haematol. 2021 Nov;195(3):399-404. doi: 10.1111/bjh.17734. Epub 2021 Jul 28. Br J Haematol. 2021. PMID: 34318932
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).
Rigacci L, Battistini R, Kovalchuk S, Zoli V, Puccini B, Evangelista A, Arcaini L, Flenghi L, Visco C, Mian M, Di Rocco A, Peracchio C, Gotti M, Tisi MC, Palombi F, Pozzi S, Gioia D, Viero P, Martelli M. Rigacci L, et al. Among authors: palombi f. Hematol Oncol. 2022 Oct;40(4):609-616. doi: 10.1002/hon.3028. Epub 2022 Jun 5. Hematol Oncol. 2022. PMID: 35612350 Clinical Trial.
Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Arcese W, Mengarelli A; Rome Transplant Network. Renzi D, et al. Among authors: palombi f. Chemotherapy. 2017;62(1):58-61. doi: 10.1159/000448750. Epub 2016 Sep 10. Chemotherapy. 2017. PMID: 27618144 Free article.
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Marchesi F, Pimpinelli F, Dessanti ML, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Maschio M, Ensoli F, Mengarelli A. Marchesi F, et al. Among authors: palombi f. Transpl Infect Dis. 2014 Dec;16(6):1032-8. doi: 10.1111/tid.12309. Epub 2014 Nov 5. Transpl Infect Dis. 2014. PMID: 25369809
83 results